Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ulviprubart

A humanized, afucosylated monoclonal antibody directed against killer cell lectin-like receptor G1 (KLRG1), with potential immunomodulatory activity. Upon administration, anti-KLRG1 monoclonal antibody ABC008 targets and binds to KLRG1 expressed on highly differentiated effector CD8+ cytotoxic T cells, and selectively depletes these highly differentiated cytotoxic T cells while sparing other immune cells. This prevents the killing of cells by these highly differentiated cytotoxic T cells in certain autoimmune diseases, such as the destruction of muscle tissue in inclusion body myositis, and the destruction of neutrophils and red blood cell precursors in T-cell large granular lymphocytic leukemia (T-LGLL).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:ABC 008
ABC-008
ABC008
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search